TY -的T1 - IV组织纤溶酶原激活物用于急性中风JF -神经学乔-神经病学SP - 306 LP - 312——10.1212/01. w首页nl.0000196478.77152。fc六世- 66 - 3 AU - y z邓AU - m·j·里夫斯盟b . s . Jacobs AU - g . l . Birbeck AU - r .美国Kothari AU - s . l . Hickenbottom盟a·j·穆拉德AU - s韦娜盟- k·马德克斯盟a·马吉德A2 - Y1 - 2006/02/14 UR - //www.ez-admanager.com/content/66/3/306.abstract N2 -目的:评估使用静首页脉注射重组组织纤溶酶原激活物(rt-PA)全州医院卒中注册表,并确定其使用的相关因素中符合条件的患者。修改方法:分层抽样方案是用于获得一个具有代表性的16医院。未来的情况下确定和数据收集被用来识别所有急性中风招生超过6个月的时间。主体资格IV rt-PA被定义为那些在3小时内到达发作,没有证据表明出血大脑最初的形象,并没有与IV rt-PA physician-documented原因不。多变量逻辑回归是用来确定IV rt-PA使用的相关因素。结果:2566年中风招生,330(12.9%)达到了合格标准rt-PA治疗,和这些43(13%)接受了静脉rt-PA治疗。Among 2,236 admissions excluded from consideration, 21% had evidence of hemorrhage on initial imaging, 35% had unknown stroke onset times, 38% had an onset to arrival time >3 hours, and 6% had physician documented contraindications. Among eligible patients, being male, use of emergency medical services, and rapid presentation were associated with increased IV rt-PA use. Conclusions: Treatment with IV rt-PA was underutilized in this hospital-based stroke registry. The primary reason for nontreatment was delayed presentation. Reducing prehospital and in-hospital response times would help increase IV rt-PA use, as would greater emergency medical services use. Improving the documentation of onset times would help clarify the underlying causes of delayed presentation. ER -